Similar articles

• LMO2 and gene therapy for severe combined immunodeficiency.

  Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M. Fischer A, et al. N Engl J Med. 2004 Jun 10;350(24):2526-7; author reply 2526-7. doi: 10.1056/NEJM200406103502422. N Engl J Med. 2004. PMID: 15190153 No abstract available.
• Gene therapy insertional mutagenesis insights.

  Davé UP, Jenkins NA, Copeland NG. Davé UP, et al. Science. 2004 Jan 16;303(5656):333. doi: 10.1126/science.1091667. Science. 2004. PMID: 14726584 No abstract available.
• LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

  Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. Hacein-Bey-Abina S, et al. Science. 2003 Oct 17;302(5644):415-9. doi: 10.1126/science.1088547. Science. 2003. PMID: 14564000
• Occurrence of leukaemia following gene therapy of X-linked SCID.

  Kohn DB, Sadelain M, Glorioso JC. Kohn DB, et al. Nat Rev Cancer. 2003 Jul;3(7):477-88. doi: 10.1038/nrc1122. Nat Rev Cancer. 2003. PMID: 12835668 Review.
• Genotoxicity of retroviral integration in hematopoietic cells.

  Nienhuis AW, Dunbar CE, Sorrentino BP. Nienhuis AW, et al. Mol Ther. 2006 Jun;13(6):1031-49. doi: 10.1016/j.ymthe.2006.03.001. Epub 2006 Apr 19. Mol Ther. 2006. PMID: 16624621 Review.